Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8790130 | Urologic Oncology: Seminars and Original Investigations | 2018 | 11 Pages |
Abstract
These studies demonstrate the immunomodulatory properties of M7824 on both tumor cell phenotype and immune-mediated lysis. Compared to anti-PD-L1 or M7824mut, M7824 induces immunogenic modulation of urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. These findings show the relevance of the dual blockade of PD-L1 and TGFβ in urothelial carcinoma cell lines and thus support the rationale for future clinical studies of M7824 in patients with urothelial cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Italia M.D., Renee N. Ph.D., Morgan L. B.S., Lauren M. Ph.D., Mario M.D., Ph.D., Marijo M.D., Ph.D., Jeffrey Ph.D.,